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Statement of findings
To determine whether IL-4 is therapeutic in treating established experimental arthritis, a
recombinant adenovirus carrying the gene that encodes murine IL-4 (Ad-mIL-4) was used for
periarticular injection into the ankle joints into mice with established collagen-induced
arthritis (CIA). Periarticular injection of Ad-mIL-4 resulted in a reduction in the severity of
arthritis and joint swelling compared with saline and adenoviral control groups. Local
expression of IL-4 also reduced macroscopic signs of joint inflammation and bone erosion.
Moreover, injection of Ad-mIL-4 into the hind ankle joints resulted in a decrease in disease
severity in the untreated front paws. Systemic delivery of murine IL-4 by intravenous injection
of Ad-mIL-4 resulted in a significant reduction in the severity of early-stage arthritis.
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Ad-eGFP = enhanced green fluorescent protein; Ad-mIL-4 = adenovirus carrying the gene that encodes murine IL-4; CIA = collagen-induced arthri-
tis; ELISA = enzyme-linked immunosorbent assay; IL-1Ra = IL-1 receptor antagonist; RA = rheumatoid arthritis; Th = T-helper (cells); TNF = tumor
necrosis factor.
Introduction: Rheumatoid arthritis (RA) is a chronic systemic
autoimmune disease that is characterized by joint inflammation,
and progressive cartilage and bone erosion. Recent research
has identified certain biologic agents that appear more able than
conventional therapies to halt effectively the progression of
disease, as well as ameliorate disease symptoms. One potential
problem with the use of biologic agents for arthritis therapy is
the need for daily or weekly repeat dosing. The transfer of genes
directly to the synovial lining can theoretically circumvent the
need for repeat dosing and reduce potential systemic side
effects [1,2]. However, although many genes have been
effective in treating murine CIA if administrated at a time before
disease onset, local intra-articular or periarticular gene transfer
has not been highly effective in halting the progression of
established disease. IL-4, similar to tumor necrosis factor
(TNF)-a and IL-1 inhibitors, has been shown be therapeutic for
the treatment of murine CIA when administered intravenously as
a recombinant protein, either alone or in combination with IL-10.
IL-4 can downregulate the production of proinflammatory and
T-helper (Th)1-type cytokines by inducing mRNA degradation
and upregulating the expression of inhibitors of proinflammatory
cytokines such as IL-1 receptor antagonist (IL-1Ra) [3,4]. IL-4 is
able to inhibit IL-2 and IFN-g production by Th1 cells, resulting in
suppression of macrophage activation and the production of the
proinflammatory cytokines IL-1, IL-6, IL-8, and TNF-a by mono-
cytes and macrophages [4–9].
Objective: In order to examine the therapeutic effects of local
and systemic IL-4 expression in established CIA, an adenoviral
vector carrying the gene for murine IL-4 (Ad-mIL-4) was
generated. The ability of Ad-mIL-4 to treat established CIA was
evaluated by local periarticular and systemic intravenous injection
of Ad-mIL-4 into mice at various times after disease onset.
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Materials and methods: Male DBA/1 lacJ (H-2q) mice, aged
7–8 weeks, were purchased from The Jackson Laboratory (Bar
Harbor, ME, USA). The mice were immunized intradermally at
the base of tail with 100mg bovine type II collagen. On day 21
after priming, mice received a boost injection (intradermally)
with 100mg type II collagen in incomplete adjuvant. For the
synchronous onset of arthritis, 40mg lipopolysaccharide
(Sigma, St Louis, MO, USA) was injected intraperitoneally on
day 28. Ad-mIL-4 was injected periarticularly into the hind ankle
joints of mice on day 32 or intravenously by tail vein injection on
day 29. Disease severity was monitored every other day using
an established macroscopic scoring system ranging from 0 to
4: 0, normal; 1, detectable arthritis with erythma; 2, significant
swelling and redness; 3, severe swelling and redness from joint
to digit; and 4, maximal swelling with ankylosis. The average of
macroscopic score was expressed as a cumulative value for all
paws, with a maximum possible score of 16 per mouse.
Cytokine production by joint tissue or serum were assessed
using enzyme-linked immunosorbent assay (ELISA; R&D
Systems, Minneapolis, MN, USA).
Results: To examine the therapeutic effects of IL-4 gene
transfer in a murine model of arthritis, 5×108 particles of
Ad-mIL-4 and enhanced green fluorescent protein (Ad-eGFP)
were administered by periarticular injection into the ankle joints
of mice with established disease 4 days after lipopoly-
saccharide injection. All mice had established disease at time
of injection. As shown in Figure 1, the severity of arthritis
(Fig. 1a), paw thickness (Fig. 1b), and the number of arthritic
paws (Fig. 1c) were all significantly reduced in the Ad-mIL-4
group, compared with the saline- and Ad-eGFP-treated groups.
Analysis of the bones in the ankle joints of control arthritic mice
showed evidence of erosion with an associated monocytic
infiltrate around the joint space compared with the Ad-mIL-4-
treated and nonarthritic control joints. In addition, injection of
the ankle joints in the hind legs resulted in a therapeutic effect
in the front paws. A similar contralateral effect has been
observed with adenoviral-mediated delivery of viral (v)-IL-10.
Interestingly, a high level of murine IL-10 also was detected
from the joint lysates of Ad-mIL-4-treated naïve and arthritic
mice, with the production of endogenous IL-10 correlating with
the dose of Ad-mIL-4. The administration of recombinant IL-4
protein systemically has been shown to be therapeutic in
murine CIA models if given before disease onset. To examine
the effect of systemic IL-4 delivered by gene transfer, 1×109
particles of Ad-mIL-4 were injected via the tail vein of collagen-
immunized mice the day after lipopolysaccharide injection.
Whereas the immunized control mice, injected with Ad-eGFP,
showed disease onset on day 3 after lipopolysaccharide
injection, Ad-mIL-4-treated mice showed a delay in disease
onset and as a reduction in the total number of arthritic paws.
Also, systemic injection of Ad-mIL-4 suppressed the severity of
arthritis in CIA mice according to arthritis index.
Discussion: Gene therapy represents a novel approach for
delivery of therapeutic agents to joints in order to treat the
pathologies associated with RA and osteoarthritis, as well as
other disorders of the joints. In the present study we examined
Figure1
Local delivery of Ad-mIL-4. Three days after lipopolysaccharide
treatment collagen-immunized mice were injected periarticularly with
5×10 8 particles of Ad-mIL-4, Ad-eGFP, or saline. (a) Arthritis index.
Subsequently, severity of disease was assessed every other day using
an established macroscopic scoring system ranging from 0 to 4: 0,
normal; 1, detectable arthritis with erythma; 2, significant swelling and
redness; 3, severe swelling and redness from joint to digit; and 4,
maximal swelling with ankylosis or necrosis. The average macroscopic
score was expressed as a cumulative value for all paws, with a
maximum possible score of 16 per mouse (n=20). *P<0.01. (b) Paw
swelling. The thickness of each paw was also evaluated using a spring-
load caliper. The paw swelling for each mouse was calculated by
adding the four thicknesses of the individual paws. *P<0.1;
**P<0.05. (c) Number of arthritic paws. At the same time, the total
number of arthritic paws were determined for each experimental group
(n = 10, maximum 40 per group). *P<0.01.http://arthritis-research.com/content/2/4/293
Introduction
RA is a chronic systemic autoimmune disease that is char-
acterized by joint inflammation, and progressive cartilage
and bone erosion. Currently the symptoms of arthritis are
managed using pharmacologic agents, including both
steroidal and nonsteroidal drugs, and disease-modifying
drugs such as methotrexate. No pharmacologic agents
have yet proven effective in halting the progression of
disease, however. Recent research has identified certain
biologic agents that appear more able than conventional
therapies to halt effectively the progression of disease, as
well as ameliorate disease symptoms. In particular,
inhibitors of TNF-a and IL-1 have proven effective in clini-
cal trials, and the US Food and Drug Administration has
approved the use of soluble TNF-a receptor for treatment
of human RA. One potential problem with the use of bio-
logic agents for arthritis therapy is the need for daily or
weekly repeat dosing. The transfer of genes directly to the
synovial lining can theoretically circumvent the need for
repeat dosing and reduce potential systemic side effects
[1,2]. Ex-vivo and in-vivo methods have been used to
deliver therapeutic genes such as those that encode
IL-10, v-IL-10, soluble TNF and IL-1 receptors, and IL-1Ra
to arthritic mouse [10], rat [11], dog [12], and rabbit joints
[13]. Although many genes have been effective in treating
murine CIA if they are administered before disease onset,
local periarticular gene transfer has not been highly effec-
tive in halting the progression of established disease.
IL-4, similar to TNF-a and IL-1 inhibitors, has been shown
be therapeutic for the treatment of murine CIA when
administered intravenously as a recombinant protein,
either alone or in combination with IL-10. IL-4 can down-
regulate the production of proinflammatory and Th1-type
cytokines by inducing mRNA degradation and upregulat-
ing the expression of inhibitors of proinflammatory
cytokines such as IL-1Ra [3,4]. IL-4 is able to inhibit IL-2
and IFN-g production by Th1 cells, resulting in suppres-
sion of macrophage activation and the production of the
proinflammatory cytokines IL-1, IL-6, IL-8, and TNF-a by
monocytes and macrophages [5–9]. In addition, IL-4
inhibits growth factor-induced RA synoviocyte prolifera-
tion, and expression of prostaglandin E and matrix metallo-
proteinase-3 in RA synovial fibroblast [14–16], and
reduces bone resorption. Given that IL-4 is able to inhibit
the production of both IL-1 and TNF-a, block synovial cell
proliferation and bone loss, and promote the formation of
Th2 lymphocytes, it represents an attractive cytokine for
treating arthritis by gene transfer.
To examine the therapeutic effects of local and systemic
IL-4 expression in established CIA, we have generated an
adenoviral vector carrying the gene for murine IL-4
(Ad-mIL-4). The ability of Ad-mIL-4 to treat established
CIA was evaluated by local periarticular and systemic
intravenous injections of Ad-mIL-4 into mice at various
times after disease onset. Local injection of Ad-mIL-4
resulted in a reduction in the severity of arthritis and joint
swelling, and reduced macroscopic signs of joint inflam-
mation and bone erosion. Injection of the ankle joints in
the hind legs also resulted in a therapeutic effect in the
untreated, front paws. A high level of endogenous murine
IL-10 was detected in the joint tissues of mice injected
locally with Ad-mIL-4. Systemic delivery of murine IL-4 by
intravenous injection of Ad-mIL-4 also resulted in a slight
delay in the onset of disease, with a significant reduction
in the number of arthritic paws. These results demonstrate
that local and systemic gene transfer of IL-4 is able to treat
established and early-stage disease, respectively, in a
mouse model of arthritis, and thus may be useful for clini-
cal applications for the treatment of RA.
Materials and methods
Mice
Male DBA/1 lacJ (H-2q) mice, aged 7–8 weeks, were pur-
chased from The Jackson Laboratory. They were main-
tained in a specific pathogen-free animal facility of the
University of Pittsburgh Biotechnology Center. For local
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the ability of local periarticular and systemic gene transfer of
IL-4 to treat established and early-stage murine CIA,
respectively. We have demonstrated that both local and
systemic administration of Ad-mIL-4 resulted in a reduction in
the severity of arthritis, as well as in the number of arthritic
paws. In addition, the local gene transfer of IL-4 reduced
histologic signs of inflammation and of bone erosion.
Interestingly, local delivery of Ad-mIL-4 was able to confer a
therapeutic effect to the untreated, front paws through a
currently unknown mechanism. In addition, both local and
systemic expression of IL-4 resulted in an increase in the level
of endogenous IL-10, as well as of IL-1Ra (data not shown).
Previous experiments have shown that gene transfer of IL-10
and IL-1 and TNF inhibitors at the time of disease initiation (day
28) is therapeutic. However, delivery of these agents after
disease onset appeared to have only limited therapeutic effect.
In contrast, the present results demonstrate that IL-4, resulting
from local periarticular and systemic injection of Ad-mIL-4, was
able partially to reverse progression of established and early-
stage disease, respectively. These results, as well as those of
others, support the potential application of IL-4 gene therapy
for the clinical treatment of RA.periarticular injection, mice were anesthetized with inhala-
tion of 2.5% isoflurane gas. A maximum of 5ml diluted aden-
ovirus was injected into joint articular space under the ankle
joint bone in each hind paw with a 26-gauge Hamilton
syringe. For systemic delivery of adenovirus, 500ml diluted
adenovirus was injected intravenously via the tail vein.
Vector construction and adenovirus generation
Ad-mIL-4 was constructed and propagated according to
standard protocols, as previously described [17]. Briefly,
recombinant adenoviruses were generated by homolo-
gous recombination in CRE8 cells, a 293 cell line that
expresses Cre recombinase, between psi-5, an
Ad5-derived, E1- and E3-deleted adenovirus, and pAd-lox,
the adenoviral shuttle vector that expresses IL-4. The
inserted cDNA sequences are expressed under the tran-
scriptional control of human cytomegalovirus promoter.
Vectors were purified using two consecutive CsCl gradi-
ent ultracentrifugation, dialyzed at 4°C against sterile virus
buffer, aliquoted, and stored at –80°C until use. The titers
of the adenoviral stocks were determined by incubating
serial dilutions of the stocks at 37°C for 60 min with sub-
confluent 293 cells. Viral titers were calculated by deter-
mining the highest dilution that produced 100% viral
cytopathic effect, which was then multiplied by the
number of cells per well and by the dilution factor. CRE8
and 293 cell lines were grown in Dulbecco’s modified
eagle medium (GIBCO-BRL, Rockville, MD, USA) supple-
mented with 10% fetal bovine serum.
Induction of arthritis
Bovine type II collagen (Chondrex, Seattle, WA, USA) was
dissolved in 0.05mol/l acetic acid at a concentration of
2mg/ml by stirring overnight at 4°C and emulsified in equal
volumes of FCA containing 2mg/ml heat-killed Mycobac-
terium tuberculosis strain H37Ra. The mice were immu-
nized intradermally at the base of tail with 100mg collagen.
On day 21 after priming, the mice were boosted with
100mg type II collagen in incomplete adjuvant. In order to
synchronize the onset of arthritis, 40mg lipopolysaccharide
(Sigma) was injected intraperitoneally on day 28.
Disease evaluation
Disease severity was assessed every other day using an
established macroscopic scoring system ranging from 0
to 4: 0, normal; 1, detectable arthritis with erythma; 2,
significant swelling and redness; 3, severe swelling and
redness from joint to digit; and 4, maximal swelling with
ankylosis. The macroscopic score (mean ± standard
deviation) was expressed as a cumulative value for all
paws, with a maximum possible score of 16. The thick-
ness of each paw was also measured using a spring-load
caliper. The paw swelling for each mouse was calculated
by adding the four thicknesses of the individual paws. In
addition, the number of arthritic paws of individual mice
were counted and added to represent the number of
arthritic paws in a group. The in vivo experiments were
performed with 10 mice/group and repeated three times
to ensure reproducibility.
Histologic examination
Joint tissues from freshly dissected mice were immersion-
fixed in 10% neutral buffered formalin and decalcified in
15% ethylene diamine tetra-acetic acid/30% glycerol for 2
weeks. Tissues were then dehydrated in graded alcohols,
embedded in paraplast, sectioned at 5mm on a microtome,
and stained with hematoxylin and eosin. Sections were eval-
uated in a blinded manner for histologic signs of arthritis
and scored as follows: 1, synovial cell proliferation, synovial
hypertrophy with villus formation and/or fibrin deposition; 2,
inflammation, synovitis and/or generalized inflammation; 3,
cartilage disruption, chondrocyte degeneration and/or ruf-
fling of cartilage surface and/or dystrophic cartilage; and 4,
joint destruction, cartilage erosion with abundant inflamma-
tion and pannus formation with bone erosion.
Type II collagen antibody titration
Serum level of antibody against type II collagen was mea-
sured using a standard ELISA assay. Briefly, a 96-well
Immuno-Maxisorp Plate (Nunc, Naperville, IL, USA) was
coated with bovine type II collagen (10mg/ml) overnight at
4°C and blocked with 10% fetal bovine serum in phos-
phate-buffered saline. Sample sera were diluted to
1:100000 (vol:vol) and incubated for 2 h at 37°C. After
washing, bound antibody isotope was detected with
biotin-conjugated antimouse whole IgG (heavy and light
chain) antibody (Pharmingen, San Diego, CA, USA).
Thereafter, plates were washed, incubated with 100ml
2,2-azino-di-(-3-ethyl-benzthiazolinesulfonate) substrate
(ABTS; Boeringer Mannheim, Indianapolis, IN, USA) at
1mg/ml and read at 405nm.
Cytokine production
Cytokine production in the joint tissue or serum was
assessed by ELISA (R&D systems). For measuring the
cytokine production, peeled joint tissues from the upper
portion of ankle to the middle of the paw were ground by
homogenizer in the equal volume of the lysis buffer
(100mmol/l potassuim phosphate, pH 7.8 and 0.2%
Triton-X 100). Cytokine production was standardized as
amount of cytokine per gram of tissue.
Statistical analysis
Results were compared using the Student’s t-test and by
analysis of variance. P<0.05 was considered statistically
significant.
Results
Local delivery of Ad-mIL-4 in established CIA mouse model
To establish CIA, 8-week-old aged DBA1/lacJ male mice
were immunized with 100mg bovine type II collagen emul-
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boosted with the same amount of collagen in incomplete
adjuvant, with disease pathology observed starting 28
days after immunization. In order to synchronize the onset
of arthritis, lipopolysaccharide was injected intraperi-
toneally on day 28, excluding the mice that had already
showed signs of disease pathology. All of the collagen-
immunized mice had swollen and red paws and ankle
joints within 3 days after lipopolysaccharide injection.
In order to examine the therapeutic effects of IL-4 gene
transfer in a murine model of arthritis, increasing doses of an
Ad-mIL-4 recombinant virus were administered by periartic-
ular injection into the hind ankle joints of mice with estab-
lished disease 4 days after lipopolysaccharide injection.
As shown in Figure 1, all mice had established disease at
time of injection. However, the severity of arthritis (Fig. 1a),
paw thickness (Fig. 1b), and the number of arthritic paws
(Fig. 1c) were all significantly reduced in the Ad-mIL-4
group, compared with the saline- and Ad-eGFP-treated
groups.
Analysis of the bones in the ankle joints of control arthritic
mice showed evidence of erosion with an associated
monocytic infiltrate around the joint space (Fig. 2a) com-
pared with the nonarthritic control joints. In contrast, the
joints from Ad-mIL-4-treated mice showed less inflamma-
tory joint tissue, reduction in bone erosion, and reduction
in the number of inflammatory cells. The changes in histol-
ogy of the ankle joints from sections from five mice per
group were also scored in a blinded manner. As shown in
Figure 2b, significant inhibition of disease progression as
assessed by joint histology was observed in the
Ad-mIL-4-treated group.
These results suggest that local expression of IL-4 after
gene transfer to joints with established disease could
effectively protect tissue from inflammation as well as
block bone erosion. It is important to note that the possi-
ble inflammatory responses to adenoviral injection were
examined by injection of the same number of particles of
Ad-mIL-4 and Ad-eGFP into naïve joints of DBA mice. At
the doses of virus used, however, no inflammation was
observed (data not shown).
Reduction in disease severity in noninjected front paws by
local injection of IL-4
Previously, we have noted a contralateral effect, in which
treatment of a diseased joint by adenovirus-mediated
transfer of the gene that encodes v-IL-10 resulted in a
therapeutic effect in noninjected joints. To determine
whether Ad-mIL-4 was able to confer a contralateral
effect, the severity of disease in the hind and front paws of
the mice injected only in the hind ankle joints was evalu-
ated. As shown in Figure 3a, a reduction in the arthritis
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Figure 2
Histological analysis of the effect of local Ad-mIL-4 treatment in CIA. (a) Ankle joints of mice were isolated from CIA and same-aged normal DBA
mice 28 days after adenovirus injection. Ankle joint tissues were stained with hematoxylin and eosin and showed 100× magnification. Particles of
Ad-IL-4 or Ad-eGFP (5×108) were injected into ankle joints of mice with established CIA. (b) The joint tissue sections were evaluated in a blinded
manner and scored as follows: 1, synovial cell proliferation, synovial hypertrophy with villus formation and/or fibrin deposition; 2, inflammation,
synovitis and/or generalized inflammation; 3, cartilage disruption, chondrocyte degeneration and/or ruffling of cartilage surface and/or dystrophic
cartilage; and 4, joint destruction, cartilage erosion with abundant inflammation and pannus formation with bone erosion. A total of five joints per
group were evaluated by at least two individuals in a blinded manner.index was observed in the Ad-mIL-4 injected hind leg
ankle joints of the CIA mice. Interestingly, the noninjected
front paws also showed a statistically significant reduction
in the severity of arthritis (Fig. 3b). Taken together, these
results suggest that local periarticular injection of
Ad-mIL-4 resulted in a therapeutic effect in both injected
and noninjected joints. However, unlike v-IL-10, IL-4 is
able to confer a contralateral therapeutic effect in mice
with established disease.
Stimulation of endogenous IL-10 expression by local IL-4
gene delivery
To test the level and duration of gene expression, 5×108
particles of Ad-mIL-4, Ad-mIL-10, and Ad-eGFP were
injected periarticularly into the ankle joints of naïve DBA1
mice. Joint tissues were isolated at indicated time points,
homogenized in lysis buffer, and the lysates analyzed for
cytokine production by ELISA. Maximal IL-4 expression
was detected on day 7, with the level gradually decreasing
over time (Fig. 4a). However, it is important to note that it
is unclear whether the level of IL-4 detected in the joints at
the different time points is partially due to induction of
endogenous IL-4. Interestingly, a high level of murine IL-10
also was detected from the joint lysates of Ad-mIL-4-
injected animals (Fig. 4b) that directly correlated with the
dose of Ad-mIL-4 (data not shown). An increase in the
level of IL-10 expression could even be detected 3 weeks
after injection of a high dose of Ad-mIL-4.
The levels of IL-4 and IL-10 expression also were exam-
ined in arthritic mice treated with Ad-mIL-4 at day 35 after
injection. As shown in Figure 5a, a slight increase in IL-4
expression was observed in that correlated with the dose
of Ad-mIL-4 (Fig. 5a). A similar increase at day 35 was
also observed in naïve mice (data not shown). In addition,
a significant dose-dependent increase in the level of
endogenous IL-10 35 days after Ad-mIL-4 administration
was observed in the CIA-treated animals (Fig. 5b). These
results demonstrated that IL-4 transgene expression was
detectable for up to 5 weeks after Ad-mIL-4 delivery and
that IL-4 was able to induce the production of endoge-
nous IL-10 in the joints of both naïve and immunized mice.
In addition, expression of IL-4 resulted in a twofold
increase in the level of endogenous IL-1Ra (data not
shown). In contrast, periarticular injection of Ad-mIL-10
did not affect the level of expression of endogenous levels
of IL-4 (Fig. 4a) and IL-1Ra (data not shown). Taken
together, these results suggest that the therapeutic
effects of exogenous IL-4 could be mediated in part
through the induction of endogenous IL-4 and IL-1Ra.
Delay of disease onset by systemic Ad-mIL-4
administration
The administration of recombinant IL-4 protein systemically
has been shown to be therapeutic in murine CIA models if
given before onset of disease onset. To examine the effect
of systemic IL-4 delivered by gene transfer, 109 particles of
Ad-mIL-4 were administered intravenously by tail vein injec-
tion of the collagen-immunized mice on the day after
lipopolysaccharide injection. Whereas the immunized mice
injected with Ad-eGFP showed disease onset on day 3
after lipopolysaccharide injection, IL-4-treated mice
showed a delay in disease onset (Fig. 6a) as well as a
reduction in the total number of arthritic paws (Fig. 6c). In
addition, seven out of the 15 Ad-mIL-4-treated mice were
disease-free for up to 10 days after lipopolysaccharide
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Figure 3
Periarticular injection of Ad-mIL-4 into the hind leg ankle joints conferred a therapeutic effect in the untreated, front paws. The arthritic mice injected
in the hind leg ankle joints with Ad-mIL-4, Ad-eGFP or saline were evaluated for the severity of arthritis in either the hind, treated paws (a) or front,
untreated paws (b). The macroscopic score (mean ± standard deviation) is expressed as a cumulative value for the two paws, with a maximum
possible score of 8.injection, and two mice were disease free at the end of the
experiment on day 65. In addition, systemic injection of Ad-
mIL-4 suppressed the severity of arthritis in the CIA mice
according to arthritis index (Fig. 6b). Thus, systemic deliv-
ery of IL-4 by adenovirus-mediated gene transfer is able to
reduce the onset and severity of early-stage disease.
IL-4 and IL-10 expression in sera of CIA mice administered
Ad-mIL-4 systemically
To examine the duration of IL-4 expression as well as
induction of endogenous IL-10 expression, serum was col-
lected from the mice and tested for levels of IL-4 and IL-10
(Fig. 7). An elevated level of IL-4 was detected in on day 7
(Fig. 7a) and on day 30 (Fig. 7c) after IL-4 injection. In
addition, although there was no observed increase in the
expression of IL-10 in the sera at day 7 after systemic
delivery of IL-4 (Fig. 7b), IL-10 was elevated in the sera at
day 35 (Fig. 7d). In contrast, the levels of IL-4 and IL-10 in
the saline or Ad-eGFP-treated control groups were not
significantly above background after either or local
Ad-mIL-4 delivery. Thus, the early therapeutic effects of
IL-4 after systemic delivery most likely are not mediated by
IL-10. In contrast, it is possible that the therapeutic effects
of IL-4 after local injection are conferred in part by IL-10.
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Figure 4 
Induction of IL-10 by Ad-mIL-4 administration. Particles of Ad-IL-4, Ad-IL-10, or Ad-eGFP (5×108) were injected into the ankle joints of naïve DBA
mice. The animals were killed at the indicated time points and joint tissue homogenized. The lysate was then monitored for (a) murine IL-4 and (b)
murine IL-10 using the appropriate ELISA.
Figure 5
Levels of expression of IL-4 and IL-10 in immunized mice after periarticular injection of diferent doses of Ad-mIL-4. Increasing doses of Ad-mIL-4
were injected periarticularly into mice with established arthritis. The animals were killed at day 35, and the joint tissue homogenized and assayed for
levels of (a) IL-4 and (b) IL-10. The doses of Ad-mIL-4 used were as follows: low, 5×106; mid, 5×107; and high, 5×108.Discussion
Gene therapy represents a novel approach for delivery of
therapeutic agents to joints in order to treat the patholo-
gies associated with RA and osteoarthritis, as well as
other disorders of the joints. Previously, we and others
have shown that local ex vivo and in vivo gene transfer of
v-IL-10, IL-1Ra, IFN-g, soluble IL-1 receptor, and soluble
TNF receptor are able to block certain intra-articular
pathologies in rabbit, rat, and murine models of arthritis.
IL-4, like IL-10, is a Th2 cytokine that has been demon-
strated to be therapeutic for the treatment of arthritis after
systemic administration of recombinant protein.
In the present study we examined the ability of local periar-
ticular gene transfer of IL-4 to treat established murine
CIA. We demonstrated that both local and systemic
administration of Ad-mIL-4 resulted in a reduction in the
severity of established and early-stage arthritis, respec-
tively, as well as in the number of arthritic paws. In addi-
tion, the local gene transfer of Ad-mIL-4 reduced
histologic signs of inflammation as well as bone erosion.
Previous experiments have shown that gene transfer of
IL-10 and IL-1 and TNF inhibitors at the time of disease ini-
tiation (day 28) was therapeutic. However, delivery of
these agents after disease onset appeared to have only
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Figure 6
Systemic delivery of Ad-mIL-4. Adenoviruses were injected into the tail
vein 24 h after lipopolysaccharide treatment. (a) Arthritis index.
Subsequently, severity of disease was assessed every other day using
an established macroscopic scoring system ranging from 0 to 4: 0,
normal; 1, detectable arthritis with erythma; 2, significant swelling and
redness; 3, severe swelling and redness from joint to digit; and 4,
maximal swelling with ankylosis or necrosis. +The average
macroscopic score was expressed as a cumulative value for all paws,
with a maximum possible score of 16 per mouse (n=10). *P<0.001;
**P<0.0005. (b) Paw swelling. The thickness of each paw was also
evaluated using a spring-load caliper. The paw swelling for each
mouse was calculated by adding the four thicknesses of the individual
paws. *P<0.05; **P<0.001. (c) Number of arthritis paws. The total
number of arthritic paws were determined for each experimental group
(maximum 40 per group). *P<0.001.
Figure 7
Serum IL-4 and IL-10 levels following systemic Ad-mIL-4 delivery
Ad-mIL-4 was delivered to mice by tail vein injection 30 days after
immunization. A week and 30 days after Ad-mIL-4 and Ad-eGFP
injection, the mice were bled and serum levels of cytokines measured
by ELISA. (a) IL-4 secretion on day 7, (b) IL-10 secretion on day 7,
(c) IL-4 secretion on day 30, and (d) IL-10 secretion on day 30.limited therapeutic effect. In contrast, the present results
demonstrate that local IL-4 delivery was able partially to
reverse progression of established disease after local peri-
articular injection.
Interestingly, local and systemic expression of IL-4
resulted in an increase in the level of endogenous IL-10 as
well as IL-1Ra. Previous reports have shown that an addi-
tive or possible synergistic therapeutic effect can be
achieved in animal models of arthritis with combined treat-
ment with recombinant IL-4 and IL-10. Treatment of mice
with IL-4 and IL-10 results in reduction in TNF-a and IL-1b
production with a concomitant shift in the IL-1Ra:IL-1 ratio
[18,19]. The fact that the therapeutic effects of IL-4 and
IL-10 are potentially synergistic is possibly due to the fact
that they suppress proinflammatory mediator production
through different mechanisms. IL-4 is able to block tran-
scription of TNF and IL-1 genes, whereas IL-10 stimulates
degradation of TNF and IL-1b mRNAs [20]. Thus, it is
likely that the therapeutic effects we observed after local
injection of Ad-mIL-4 are due to both exogenous IL-4 and
endogenous IL-10 production. However, the delayed
induction of IL-10 after systemic administration of
Ad-mIL-4 suggests that the initial therapeutic effects are
not conferred by IL-10.
A mechanism whereby IL-4 may alter IL-10 and IL-1Ra
levels could involve the regulation of transcription factors
that regulate the respective genes for these cytokines. In
particular, nuclear factor-kB and signal transducer and
activator of transcription-6 are important for conferring
transcriptional regulation by IL-4. Signal transducer and
activator of transcription-6, after tyrosine phosphorylation,
can bind directly to nuclear factor-kB [21], resulting in
synergic activation in certain cell types.
The present results suggest that gene transfer of IL-4 can
stimulate expression of endogenous cytokines, such as
IL-10 and IL-1Ra, as well as possibly endogenous IL-4
expression. Endogenous IL-10, which can be induced by
IL-4, is a natural suppressor of a number of inflammatory
responses. Inhibition of endogenous IL-10 with neutraliz-
ing antibodies enhanced endotoxic shock, IgG immune
complex-induced lung injury, and the severity of CIA
[22–25]. Periarticular delivery of murine or viral IL-10 by
gene transfer resulted in the inhibition of CIA in mouse
models [10,26] if delivered before or at the time of
disease onset. The present results are also consistent
with the observation that IL-4, but not IL-10, has been
shown to enhance the production of IL-1Ra by RA syn-
ovial cells [14,27].
IL-4 is a potent mediator in shifting the balance of
Th1/Th2 cells and skewing the production of antibody
subtypes [28]. Th2 effector cell differentiation also is
dependent on the presence of IL-4 during priming [29].
Blocking endogenous IL-4 using neutralizing antibodies
has been shown [30] to result not only in the absence of
T cells with a Th2-like phenotype, but also in the appear-
ance of T cells producing IL-2 and IFN-g after restimula-
tion. IL-4 is also able to skew the production of antibody
subtype [28]. However, we have shown that anticollagen
antibody levels are already very high at day 30 after immu-
nization and that IL-4 treatment did not significantly
change these elevated levels (data not shown). In addition,
we did not observe significant differences between IgG
isotypes in the control and Ad-mIL-4 treated mice (data
not shown). Thus, the mechanisms through which local
and systemic IL-4 administration are able to suppress CIA
are still unclear.
We have demonstrated previously that periarticular injec-
tion of adenovirus-mediated gene transfer of v-IL-10 into
the hind paws of mice with early-stage arthritis was able to
confer a therapeutic effect in the untreated front paws.
Similarly, administration of v-IL-10 into one knee of rabbits
with antigen-induced arthritis was able to confer a thera-
peutic effect in the contralateral untreated knee. This
observed contralateral effect was not limited to v-IL-10, in
that coadministration of adenoviral vectors expressing
soluble IL-1 and soluble TNF receptors also conferred a
similar protective effect to untreated knees. Although the
mechanism of the contralateral effect is unclear, we have
demonstrated that adoptive transfer of dendritic cells from
animals treated with adenovirus-mediated gene transfer of
v-IL-10 to untreated immunized animals is able to confer a
therapeutic effect (unpublished data). Thus, it is possible
that local expression of v-IL-10 or IL-1 and TNF inhibitors
modulates the activity of dendritic cells. However,
although v-IL-10 is able to block early-stage disease, it is
ineffective in reversing established disease. In contrast,
periarticular injection of Ad-mIL-4 was able to reverse
pathology in established disease not only in the treated
hind paws, but also in the untreated front paws. Interest-
ingly, we have observed that intravenous injection of naïve
dendritic cells, genetically modified to express IL-4, is able
to effectively treat established arthritis by inhibiting the
Th1 response (unpublished data).
During the preparation of this manuscript, a similar study
using a recombinant Ad-mIL-4 vector for treatment of
murine CIA was reported [31]. However, the vector was
administered before onset of disease into knee joints,
whereas the vector in the present study was injected after
disease onset into ankle joints. Similar to the present
results, in that study local injection of the recombinant
Ad-mIL-4 vector resulted in a reduction in bone erosion
and a reduction in cartilage degradation. However, unlike
the present results, no effect on joint inflammation was
observed. Moreover, in the present report we demon-
strated that both local and systemic injection resulted in
induction of endogenous IL-10. Given the ability of IL-4 to
http://arthritis-research.com/content/2/4/293reverse established disease partially, our studies, as well
as those of others, support the potential application of IL-4
gene therapy for the clinical treatment of RA.
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